公开(公告)号：US09687572B2

公开(公告)日：2017-06-27

申请号：US13991812

申请日：2011-12-06

申请人： John W. Babich ,  John L. Joyal ,  Craig Zimmerman

发明人： John W. Babich ,  John L. Joyal ,  Craig Zimmerman

IPC分类号： A61K51/04 ,  A61K51/06

CPC分类号： A61K51/0497 ,  A61K51/065

摘要： A dendrimer conjugate according to Formula (I), or its pharmaceutically acceptable salt, or solvate thereof: and complexes of Formula I conjugates with metals radionuclides of elements such as rhenium, technetium, yttrium, lutetium and others to provide a complex for imaging tissues or for the radiotherapeutic treatment of cancer tissue. Such complexes are specific to PSMA protein and can therefore be used in imaging or treating cancer of the prostate and other tissue where the protein is expressed.

公开(公告)号：US08926944B2

公开(公告)日：2015-01-06

申请号：US13566849

申请日：2012-08-03

申请人： John W. Babich ,  Craig Zimmerman ,  John L. Joyal ,  Genliang Lu

发明人： John W. Babich ,  Craig Zimmerman ,  John L. Joyal ,  Genliang Lu

IPC分类号： A61K51/04 ,  A61K49/00 ,  C07F5/00 ,  C07D257/02 ,  C07D255/02

CPC分类号： C07D257/02 ,  A61K49/0002 ,  A61K51/0478 ,  A61K51/0482 ,  C07D255/02 ,  C07D403/14 ,  C07F5/003

摘要： Compounds according to Formula I and Formula II are potent inhibitors of PSMA activity: The invention also provides pharmaceutical compositions of a complex of a radionuclide and a Formula I compound or a Formula II compound and methods of using the radionuclide complex of a Formula I compound or a Formula II compound for treating or diagnosis of a disease or a condition associated with PSMA activity.

摘要翻译： 根据式I和式II的化合物是PSMA活性的有效抑制剂：本发明还提供了放射性核素和式I化合物或式II化合物的配合物的药物组合物和使用式I化合物的放射性核素复合物或 用于治疗或诊断与PSMA活性相关的疾病或病症的式II化合物。

公开(公告)号：US20130336888A1

公开(公告)日：2013-12-19

申请号：US13991812

申请日：2011-12-06

申请人： John W. Babich ,  John L. Joyal ,  Craig Zimmerman

发明人： John W. Babich ,  John L. Joyal ,  Craig Zimmerman

IPC分类号： A61K51/04

CPC分类号： A61K51/0497 ,  A61K51/065

摘要： A dendrimer conjugate according to Formula (I), or its pharmaceutically acceptable salt, or solvate thereof: and complexes of Formula I conjugates with metals radionuclides of elements such as rhenium, technetium, yttrium, lutetium and others to provide a complex for imaging tissues or for the radiotherapeutic treatment of cancer tissue. Such complexes are specific to PSMA protein and can therefore be used in imaging or treating cancer of the prostate and other tissue where the protein is expressed.

摘要翻译： 根据式（I）的树枝状大分子缀合物或其药学上可接受的盐或溶剂化物：和式I缀合物与诸如铼，锝，钇，镥等元素的金属放射性核素的复合物，以提供用于成像组织或 用于癌组织的放射治疗。 这种复合物对PSMA蛋白质是特异性的，因此可用于成像或治疗前列腺癌和表达蛋白质的其他组织的癌症。

公开(公告)号：US20130034494A1

公开(公告)日：2013-02-07

申请号：US13566849

申请日：2012-08-03

申请人： John W. BABICH ,  Craig Zimmerman ,  John L. Joyal ,  Genliang Lu

发明人： John W. BABICH ,  Craig Zimmerman ,  John L. Joyal ,  Genliang Lu

IPC分类号： A61K51/04 ,  C07F5/00 ,  C07D257/02

CPC分类号： C07D257/02 ,  A61K49/0002 ,  A61K51/0478 ,  A61K51/0482 ,  C07D255/02 ,  C07D403/14 ,  C07F5/003

摘要： Compounds according to Formula I and Formula II are potent inhibitors of PSMA activity: The invention also provides pharmaceutical compositions of a complex of a radionuclide and a Formula I compound or a Formula II compound and methods of using the radionuclide complex of a Formula I compound or a Formula II compound for treating or diagnosis of a disease or a condition associated with PSMA activity.

摘要翻译： 根据式I和式II的化合物是PSMA活性的有效抑制剂：本发明还提供了放射性核素和式I化合物或式II化合物的配合物的药物组合物和使用式I化合物的放射性核素复合物或 用于治疗或诊断与PSMA活性相关的疾病或病症的式II化合物。